{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"columns":[{"gene":"","key":"MONDO:0975830/OMIM:620971","label":"Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2","mondoId":"MONDO:0975830","onsetQualifier":null,"recordKeys":["13951fc226ce8f760e051fce7cbf76ae6a38083007a196aea0e0117dbf8e787f","1dcb267b9b11bb6947b50d0ec55323547dfde0ef6b8f5f3ed16a7c561bb1f4a1","26ac8ee89f6edeab250a28d90f0522ce931fce7554d397bafe0132125a4fe9b4","321e09751b2fc9f56ff3093ae6f3d224cc16b9d3d450552126bc9113b1148196","35a9318490edb17cd5c3fc4413c854b20438f1802b3ce9ca26516cccdfc87ff4","3ff63fada3cad0494d375d4cc2cb1bdccced8bb941fcb19e1b47d308429c3229","4252b6ccd281b6d3958f9906a154eb1ea817c7dde0aeaa4fbb13db016dcfaab3","65e1abde128debb2bb777f02618f0ea608c1912d6538b9f84feb7e1a97807f16","75843d5e479723cea0786d5693a65dfe2e794dc27a917beda03c895bbf7d88b4","7955813ab086475a45021057cafa2d437075930bbbb86780d2f87edc008611a8","85e0ddf5174f368556425ad3bf0a29d25aa5cf1b4af890a70a6f4a044043e9bc","92120a2482c274fa1e899260de5f31f1f52b3bf390a9ef016146f0d074df7f0e","c10b6c5a3d746d60f222a96ed2eaf77cc610b8065f6074bbfd68f3de6790d60f","d1b3e2627a01d71dd94acfa4ae5ef534a70906e3c8dccfadab10d28b7777b881","f38722c0585b41dd01a6e897bdedb46ede1809cfc5a75f9dafc099ab74d50c73","f51d4c96459570eb307dc48cbbc7da431cd0fb61580392b5bc0219c4b872ef4e"],"recordQualifiers":{},"scopeLabel":"OMIM:620971","sourceIds":["OMIM:620971"],"sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."}],"comparison":{"collapseColumnsLabel":"Show initial comparisons","defaultColumnKeys":["MONDO:0975830/OMIM:620971"],"expandColumnsLabel":"Compare all source entries","intro":"Compare the original source entries. Different entries may describe different patient groups.","primaryFeatureIds":[],"scopeNoteHtml":"<p>Each column keeps its native condition scope. Initial features are displayed alphabetically, not ranked by clinical importance. Counts remain separate, and an empty cell does not mean a feature cannot occur.</p>"},"coverage":{"countRecords":16,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":16,"sourceGroups":{"omim":0,"orphanet":0,"published":16}},"features":[{"hpoId":"HP:0030872","label":"Abnormal cardiac ventricular function","primary":false},{"hpoId":"HP:0040129","label":"Abnormal nerve conduction velocity","primary":false},{"hpoId":"HP:0007018","label":"Attention deficit hyperactivity disorder","primary":false},{"hpoId":"HP:0000729","label":"Autistic behavior","primary":false},{"hpoId":"HP:0003687","label":"Centrally nucleated skeletal muscle fibers","primary":false},{"hpoId":"HP:0003236","label":"Elevated circulating creatine kinase activity","primary":false},{"hpoId":"HP:0003546","label":"Exercise intolerance","primary":false},{"hpoId":"HP:0012548","label":"Fatty replacement of skeletal muscle","primary":false},{"hpoId":"HP:0100297","label":"Increased endomysial connective tissue","primary":false},{"hpoId":"HP:0003557","label":"Increased variability in muscle fiber diameter","primary":false},{"hpoId":"HP:0001324","label":"Muscle weakness","primary":false},{"hpoId":"HP:0003326","label":"Myalgia","primary":false},{"hpoId":"HP:0100614","label":"Myositis","primary":false},{"hpoId":"HP:0003201","label":"Rhabdomyolysis","primary":false},{"hpoId":"HP:0001328","label":"Specific learning disability","primary":false},{"hpoId":"HP:0003803","label":"Type 1 muscle fiber predominance","primary":false}],"ledeHtml":"A patient-friendly description is not yet available in the ingested narrative sources for this condition.","mondoId":"MONDO:0975830","records":[{"frequencyKind":"count","key":"13951fc226ce8f760e051fce7cbf76ae6a38083007a196aea0e0117dbf8e787f","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:620971","disease_name":"Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2","evidence":"PCS","frequency_raw":"1/10","hpo_id":"HP:0007018","is_excluded":false,"label":"Attention deficit hyperactivity disorder","onset_id":null,"reference":"PMID:36799992","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"1dcb267b9b11bb6947b50d0ec55323547dfde0ef6b8f5f3ed16a7c561bb1f4a1","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:620971","disease_name":"Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2","evidence":"PCS","frequency_raw":"12/12","hpo_id":"HP:0003236","is_excluded":false,"label":"Elevated circulating creatine kinase activity","onset_id":null,"reference":"PMID:36799992","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"26ac8ee89f6edeab250a28d90f0522ce931fce7554d397bafe0132125a4fe9b4","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:620971","disease_name":"Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2","evidence":"PCS","frequency_raw":"0/2","hpo_id":"HP:0040129","is_excluded":true,"label":"Abnormal nerve conduction velocity","onset_id":null,"reference":"PMID:36799992","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"321e09751b2fc9f56ff3093ae6f3d224cc16b9d3d450552126bc9113b1148196","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:620971","disease_name":"Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2","evidence":"PCS","frequency_raw":"4/8","hpo_id":"HP:0100297","is_excluded":false,"label":"Increased endomysial connective tissue","onset_id":null,"reference":"PMID:36799992","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"35a9318490edb17cd5c3fc4413c854b20438f1802b3ce9ca26516cccdfc87ff4","raw":{"aspect":"P","body_system":"other","disease_id":"OMIM:620971","disease_name":"Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2","evidence":"PCS","frequency_raw":"9/12","hpo_id":"HP:0003546","is_excluded":false,"label":"Exercise intolerance","onset_id":null,"reference":"PMID:36799992","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"3ff63fada3cad0494d375d4cc2cb1bdccced8bb941fcb19e1b47d308429c3229","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:620971","disease_name":"Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2","evidence":"PCS","frequency_raw":"1/8","hpo_id":"HP:0003803","is_excluded":false,"label":"Type 1 muscle fiber predominance","onset_id":null,"reference":"PMID:36799992","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"4252b6ccd281b6d3958f9906a154eb1ea817c7dde0aeaa4fbb13db016dcfaab3","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"OMIM:620971","disease_name":"Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2","evidence":"PCS","frequency_raw":"0/4","hpo_id":"HP:0030872","is_excluded":true,"label":"Abnormal cardiac ventricular function","onset_id":null,"reference":"PMID:36799992","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"65e1abde128debb2bb777f02618f0ea608c1912d6538b9f84feb7e1a97807f16","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:620971","disease_name":"Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2","evidence":"PCS","frequency_raw":"2/10","hpo_id":"HP:0000729","is_excluded":false,"label":"Autistic behavior","onset_id":null,"reference":"PMID:36799992","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"75843d5e479723cea0786d5693a65dfe2e794dc27a917beda03c895bbf7d88b4","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:620971","disease_name":"Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2","evidence":"PCS","frequency_raw":"2/8","hpo_id":"HP:0100614","is_excluded":false,"label":"Myositis","onset_id":null,"reference":"PMID:36799992","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"7955813ab086475a45021057cafa2d437075930bbbb86780d2f87edc008611a8","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:620971","disease_name":"Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0012548","is_excluded":false,"label":"Fatty replacement of skeletal muscle","onset_id":null,"reference":"PMID:36799992","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"85e0ddf5174f368556425ad3bf0a29d25aa5cf1b4af890a70a6f4a044043e9bc","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:620971","disease_name":"Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2","evidence":"PCS","frequency_raw":"3/12","hpo_id":"HP:0001324","is_excluded":false,"label":"Muscle weakness","onset_id":null,"reference":"PMID:36799992","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"92120a2482c274fa1e899260de5f31f1f52b3bf390a9ef016146f0d074df7f0e","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:620971","disease_name":"Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2","evidence":"PCS","frequency_raw":"6/8","hpo_id":"HP:0003557","is_excluded":false,"label":"Increased variability in muscle fiber diameter","onset_id":null,"reference":"PMID:36799992","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"c10b6c5a3d746d60f222a96ed2eaf77cc610b8065f6074bbfd68f3de6790d60f","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:620971","disease_name":"Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2","evidence":"PCS","frequency_raw":"1/8","hpo_id":"HP:0003201","is_excluded":false,"label":"Rhabdomyolysis","onset_id":null,"reference":"PMID:36799992","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"d1b3e2627a01d71dd94acfa4ae5ef534a70906e3c8dccfadab10d28b7777b881","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:620971","disease_name":"Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2","evidence":"PCS","frequency_raw":"7/8","hpo_id":"HP:0003687","is_excluded":false,"label":"Centrally nucleated skeletal muscle fibers","onset_id":null,"reference":"PMID:36799992","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"f38722c0585b41dd01a6e897bdedb46ede1809cfc5a75f9dafc099ab74d50c73","raw":{"aspect":"P","body_system":"other","disease_id":"OMIM:620971","disease_name":"Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2","evidence":"PCS","frequency_raw":"10/12","hpo_id":"HP:0003326","is_excluded":false,"label":"Myalgia","onset_id":null,"reference":"PMID:36799992","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"f51d4c96459570eb307dc48cbbc7da431cd0fb61580392b5bc0219c4b872ef4e","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:620971","disease_name":"Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2","evidence":"PCS","frequency_raw":"2/10","hpo_id":"HP:0001328","is_excluded":false,"label":"Specific learning disability","onset_id":null,"reference":"PMID:36799992","source_release":"2026-06-23"},"sourceGroups":["published"]}],"referenceLabels":{},"references":{"causeHtml":"<p>No mapped MedlinePlus condition document in this snapshot.</p>","identityNote":"MONDO defines condition identity and route membership. Native evidence populations and narrative coverage retain their separate scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>No MedlinePlus narrative has been mapped to this MONDO condition. Feature annotations, when available, are retained below.</p>","key":"overview","title":"Condition overview"}],"sharedSources":[],"slug":"myopathy-with-myalgia-increased-serum-creatine-kinase-and-with-or-without-episodic-rhabdomyolysis-2","sourceDocuments":[],"sourceNote":"MONDO condition identity; scoped MedlinePlus enrichment where available; original HPO annotations.","takeawayHtml":"Cause information is not available in the mapped narrative sources for this condition.","title":"myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2"},"schemaVersion":1}